Novel Hemizygous IL2RG p.(Pro58Ser) Mutation Impairs IL-2 Receptor Complex Expression on Lymphocytes Causing X-Linked Combined Immunodeficiency.


Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
04 2020
Historique:
received: 23 08 2019
accepted: 06 01 2020
pubmed: 20 2 2020
medline: 5 8 2021
entrez: 20 2 2020
Statut: ppublish

Résumé

Hypomorphic IL2RG mutations may lead to milder phenotypes than X-SCID, named variably as atypical X-SCID or X-CID. We report an 11-year-old boy with a novel c. 172C>T;p.(Pro58Ser) mutation in IL2RG, presenting with atypical X-SCID phenotype. We also review the growing number of hypomorphic IL2RG mutations causing atypical X-SCID. We studied the patient's clinical phenotype, B, T, NK, and dendritic cell phenotypes, IL2RG and CD25 cell surface expression, and IL-2 target gene expression, STAT tyrosine phosphorylation, PBMC proliferation, and blast formation in response to IL-2 stimulation, as well as protein-protein interactions of the mutated IL2RG by BioID proximity labeling. The patient suffered from recurrent upper and lower respiratory tract infections, bronchiectasis, and reactive arthritis. His total lymphocyte counts have remained normal despite skewed T and B cells subpopulations, with very low numbers of plasmacytoid dendritic cells. Surface expression of IL2RG was reduced on his lymphocytes. This led to impaired STAT tyrosine phosphorylation in response to IL-2 and IL-21, reduced expression of IL-2 target genes in patient CD4+ T cells, and reduced cell proliferation in response to IL-2 stimulation. BioID proximity labeling showed aberrant interactions between mutated IL2RG and ER/Golgi proteins causing mislocalization of the mutated IL2RG to the ER/Golgi interface. In conclusion, IL2RG p.(Pro58Ser) causes X-CID. Failure of IL2RG plasma membrane targeting may lead to atypical X-SCID. We further identified another carrier of this mutation from newborn SCID screening, lost to closer scrutiny.

Identifiants

pubmed: 32072341
doi: 10.1007/s10875-020-00745-2
pii: 10.1007/s10875-020-00745-2
pmc: PMC7142052
doi:

Substances chimiques

IL2RG protein, human 0
Interleukin Receptor Common gamma Subunit 0
Multiprotein Complexes 0
Receptors, Interleukin-2 0
STAT5 Transcription Factor 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

503-514

Références

J Clin Invest. 1995 Mar;95(3):1169-73
pubmed: 7883965
Annu Rev Immunol. 2008;26:453-79
pubmed: 18062768
J Allergy Clin Immunol. 2016 Mar;137(3):940-2.e4
pubmed: 26525228
J Allergy Clin Immunol. 2017 Feb;139(2):628-633.e10
pubmed: 27444177
J Clin Invest. 1997 Dec 15;100(12):3036-43
pubmed: 9399950
J Exp Med. 2010 Feb 15;207(2):353-63
pubmed: 20142429
J Pediatr. 2005 Oct;147(4):555-7
pubmed: 16227049
J Immunol. 2006 Feb 1;176(3):1517-24
pubmed: 16424180
J Allergy Clin Immunol. 2018 Apr;141(4):1534-1537.e8
pubmed: 29391253
Immunol Rev. 2019 Jan;287(1):202-225
pubmed: 30565241
Blood. 1997 Mar 15;89(6):1968-77
pubmed: 9058718
J Exp Med. 2010 Feb 15;207(2):365-78
pubmed: 20142430
Nat Commun. 2017 Nov 13;8(1):1443
pubmed: 29129929
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S182-94
pubmed: 20042228
Blood. 2008 Nov 15;112(10):4090-7
pubmed: 18728247
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9466-70
pubmed: 7937790
J Clin Immunol. 2015 Oct;35(7):610-4
pubmed: 26407811
Blood. 1996 Nov 15;88(10):3901-9
pubmed: 8916956
Int J Hematol. 2019 May;109(5):603-611
pubmed: 30850927
Eur J Hum Genet. 2016 Oct;24(10):1473-8
pubmed: 27142677
J Exp Med. 2019 Jun 3;216(6):1311-1327
pubmed: 31040185
J Exp Med. 2019 Jun 3;216(6):1255-1267
pubmed: 31040184
Pediatr Blood Cancer. 2014 Jan;61(1):178-9
pubmed: 23940110
J Clin Immunol. 2018 May;38(4):527-536
pubmed: 29948574
N Engl J Med. 1996 Nov 21;335(21):1563-7
pubmed: 8900089
J Allergy Clin Immunol. 2012 Jul;130(1):177-83
pubmed: 22664165
Nat Immunol. 2016 Oct;17(10):1197-1205
pubmed: 27573866
Blood. 1996 Dec 1;88(11):4239-45
pubmed: 8943859
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W169-75
pubmed: 17576678
J Allergy Clin Immunol. 2014 Apr;133(4):1092-8
pubmed: 24290292
Front Immunol. 2018 Jun 22;9:1429
pubmed: 29988287
JAMA. 2014 Aug 20;312(7):729-38
pubmed: 25138334
Clin Exp Immunol. 2000 Nov;122(2):143-9
pubmed: 11091267
J Clin Invest. 1990 Nov;86(5):1623-31
pubmed: 2243135
Annu Rev Immunol. 2018 Apr 26;36:411-433
pubmed: 29677473
J Clin Immunol. 2012 Aug;32(4):690-7
pubmed: 22460439
Clin Immunol. 2000 Apr;95(1 Pt 1):39-50
pubmed: 10794431
Eur J Immunol. 1994 Feb;24(2):475-9
pubmed: 8299698
J Immunol. 2015 Dec 1;195(11):5123-35
pubmed: 26491200
Immunogenetics. 2017 Jan;69(1):29-38
pubmed: 27566612
Nat Rev Immunol. 2009 Jul;9(7):480-90
pubmed: 19543225
J Clin Invest. 1992 Mar;89(3):861-6
pubmed: 1347296
Eur J Immunol. 2014 Oct;44(10):3129-40
pubmed: 25042067
J Clin Immunol. 2015 Jul;35(5):449-53
pubmed: 26076747
J Immunol. 2012 Jul 1;189(1):161-73
pubmed: 22634617
J Cell Biol. 2012 Mar 19;196(6):801-10
pubmed: 22412018
Clin Immunol. 2019 Apr;201:30-34
pubmed: 30776520
Clin Exp Immunol. 2002 Sep;129(3):502-9
pubmed: 12197892
Clin Immunol. 2019 Apr;201:15-19
pubmed: 30742970
Blood. 2001 Sep 15;98(6):1847-51
pubmed: 11535520
Adv Immunol. 2014;121:121-90
pubmed: 24388215
Immunol Rev. 2004 Dec;202:67-83
pubmed: 15546386
J Pediatr Hematol Oncol. 2019 May;41(4):328-333
pubmed: 29939941
Nat Rev Immunol. 2001 Dec;1(3):200-8
pubmed: 11905829
Nat Commun. 2018 Mar 22;9(1):1188
pubmed: 29568061
Allergy Asthma Clin Immunol. 2019 Jan 5;15:2
pubmed: 30622570
J Clin Immunol. 2019 Feb;39(2):207-215
pubmed: 30903457
Am J Clin Pathol. 2016 Feb;145(2):251-7
pubmed: 26834123
J Immunol. 2016 Apr 1;196(7):2923-31
pubmed: 26994304

Auteurs

Elina A Tuovinen (EA)

Folkhälsan Research Center, Helsinki, Finland.
Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Rare Diseases Center and Pediatric Research Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.

Juha Grönholm (J)

Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. juha.gronholm@helsinki.fi.
Rare Diseases Center and Pediatric Research Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland. juha.gronholm@helsinki.fi.

Tiina Öhman (T)

Systems Biology Research Group and Proteomics Unit, Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.

Sakari Pöysti (S)

Department of Clinical Microbiology and Immunology, Turku University Hospital and Institute of Biomedicine, University of Turku, Turku, Finland.

Raine Toivonen (R)

Department of Clinical Microbiology and Immunology, Turku University Hospital and Institute of Biomedicine, University of Turku, Turku, Finland.

Anna Kreutzman (A)

Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

Kaarina Heiskanen (K)

Rare Diseases Center and Pediatric Research Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.

Luca Trotta (L)

Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland.

Sanna Toiviainen-Salo (S)

Department of Pediatric Radiology, HUS Medical Imaging Center, Radiology, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.

John M Routes (JM)

Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.

James Verbsky (J)

Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.

Satu Mustjoki (S)

Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.

Janna Saarela (J)

Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland.
Department of Medical Genetics, Helsinki Central University Hospital, Helsinki, Finland.
Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway.

Juha Kere (J)

Folkhälsan Research Center, Helsinki, Finland.
Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
Stem Cells and Metabolism Research Program, University of Helsinki, Helsinki, Finland.

Markku Varjosalo (M)

Systems Biology Research Group and Proteomics Unit, Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.

Arno Hänninen (A)

Department of Clinical Microbiology and Immunology, Turku University Hospital and Institute of Biomedicine, University of Turku, Turku, Finland.

Mikko R J Seppänen (MRJ)

Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Rare Diseases Center and Pediatric Research Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH